<DOC>
	<DOCNO>NCT02625415</DOCNO>
	<brief_summary>The study design test effectiveness topical B6 cream patient develop Palmar-Plantar Erythrodysesthesia ( Hand foot syndrome ) .</brief_summary>
	<brief_title>The Topical Application Vitamin B6 Palmar-Plantar Erythrodysesthesia</brief_title>
	<detailed_description>This randomized double-blind , placebo-controlled study 100 cancer patient receive chemotherapy treatment capecitabine and/or pegylated liposomal doxorubicin . The selection potential participant base inclusion exclusion criterion . Patients randomly allocate either treatment group placebo group . Treatment deliver daily ( t.d.s ) assessment take place 0 , 1 , 2 , 3 4 week . The intervention group receive application topical vitamin B6 cream hand and/or foot patient control group receive placebo . At baseline follow-up , patient group assess degree palmar-plantar erythrodysesthesia , Quality Life , need dose-limiting due PPE Pain intensity use standardized rating scale . Data analyse inferential descriptive statistic .</detailed_description>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Adult cancer patient ( &gt; 18 ) Patients receive capecitabine and/or PLD monotherapy combination agent Patients experience PPE grade 1 Willing participate Ability complete psychometric assessment . A performance status two less Eastern Cooperative Oncology Group ( ECOG Patients hypersensitivity Vitamin B . Patients preexist dermatological condition affect hand or/and foot may limit interpretation result Patients oral Pyridoxine nicotine patch Patients previous history PPE Patients whose chemotherapy discontinue week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>